U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Polypeptides for Eliciting Neutralizing Antibodies Against HIV
  1. Licensing and Collaboration Opportunities

Polypeptides for Eliciting Neutralizing Antibodies Against HIV

The technology describes conjugate polypeptide compositions that are designed to elicit antibody response against HIV. The peptides are conjugates of one gp41 capable of forming a stable coiled-coil structure and another gp41 capable of forming an alpha-helical structure. These structural elements of gp41 were identified as important for playing a role in HIV-1 cell entry. Compositions that elicit neutralizing antibodies against HIV have been elusive to date, but the subject technology may be important in realizing that goal.

Potential Commercial Applications:

  • HIV vaccines
  • Neutralizing antibodies against HIV

Competitive Advantages:



Carol Weiss

Intellectual Property:
US Application No. PCT/US00/00456
PCT Application No. 11/928,612
US Patent No. 7,311,916
Related international patent applications filed

Collaboration Opportunity:
The FDA/CBER Laboratory of Immunology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Carol Weiss at carol.weiss@fda.hhs.gov for more information.

Licensing Contact:
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-4561

OTT Reference No: E-212-2001/0
Updated: August 9, 2015